Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages

The oral drug miltefosine (MIL) was introduced in the Indian subcontinent in the year 2002 for the treatment of visceral leishmaniasis (VL). However, recent reports on its declining efficacy and increasing relapse rates pose a serious concern. An understanding of the factors contributing to MIL tole...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Deep, Deepak Kumar, Singh, Ruchi, Kulshrestha, Arpita, Wajid, Saima, Salotra, Poonam
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2018
Matèries:
Mechanisms of Resistance
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6256749/
https://ncbi.nlm.nih.gov/pubmed/30297367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00666-18
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars